In the treatment of metastatic cutaneous MM, although anti-PD1 monoclonal antibodies are the least toxic regimen, combination ICIs increase toxicity compared to chemotherapy and other targeted therapies such as BRAF inhibitors 38. Here, PDCD1 is linked to Miyoshi myopathy.